| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | birinapant | CTRPv2 | pan-cancer | AAC | 0.17 | 8e-06 |
| mRNA | GDC-0941 | GDSC1000 | pan-cancer | AAC | -0.12 | 0.0004 |
| mRNA | ML210 | CTRPv2 | pan-cancer | AAC | -0.12 | 0.0005 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | -0.12 | 0.0006 |
| mRNA | TW 37 | GDSC1000 | pan-cancer | AAC | -0.11 | 0.001 |
| mRNA | lenalidomide | FIMM | pan-cancer | AAC | 0.5 | 0.001 |
| mRNA | temsirolimus | GDSC1000 | pan-cancer | AAC | -0.11 | 0.001 |
| mRNA | Y-39983 | GDSC1000 | pan-cancer | AAC | -0.096 | 0.003 |
| mRNA | navitoclax:birinapant (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.11 | 0.003 |
| mRNA | procarbazine | CTRPv2 | pan-cancer | AAC | 0.12 | 0.003 |